Patents Assigned to GlaxoSmithKline Biologicals, s.a.
-
Patent number: 11931405Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).Type: GrantFiled: July 28, 2022Date of Patent: March 19, 2024Assignees: GlaxoSmithKline Biologicals S.A.Inventors: Jeroen Geurtsen, Jan Theunis Poolman, Kellen Cristhina Fae, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
-
Patent number: 11446370Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).Type: GrantFiled: March 18, 2020Date of Patent: September 20, 2022Assignees: Janssen Pharmaceuticals, Inc., GlaxoSmithKline Biologicals S.A.Inventors: Jeroen Geurtsen, Jan Theunis Poolman, Kellen Cristhina Fae, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
-
Patent number: 11241495Abstract: The present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.Type: GrantFiled: November 2, 2018Date of Patent: February 8, 2022Assignee: Glaxosmithkline Biologicals S.A.Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Patent number: 11040095Abstract: HRV VP2 proteins useful as components of immunogenic compositions for the induction of cross-reactive cell-mediated immunity against human rhinovirus infection; nucleic acid constructs encoding such HRV VP2 proteins.Type: GrantFiled: October 5, 2017Date of Patent: June 22, 2021Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Catherine Marie Ghislaine Gerard, Sandra Giannini, Julien Thierry Massaux
-
Patent number: 10688168Abstract: Methods and uses are provided for inducing an immune response comprising at least two administrations of an immunogenic composition comprising an M72 related antigen and wherein a subsequent administration is delayed.Type: GrantFiled: April 2, 2015Date of Patent: June 23, 2020Assignee: GlaxoSmithKline Biologicals S.A.Inventors: William Ripley Ballou, Jr., Marie-Ange Demoitie, Marie-Noelle Renelle Donner, Nadia Ouaked, Stephane Theophile Temmerman
-
Patent number: 10669318Abstract: The present invention relates to a process for conjugation of an antigen.Type: GrantFiled: March 5, 2012Date of Patent: June 2, 2020Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Ralph Leon Biemans, Pierre Duvivier, Ollivier Francis Nicolas Gavard
-
Patent number: 10646564Abstract: The present invention discloses an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.Type: GrantFiled: February 21, 2019Date of Patent: May 12, 2020Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
-
Patent number: 10583185Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.Type: GrantFiled: August 24, 2016Date of Patent: March 10, 2020Assignees: GlaxoSmithKline Biological S.A., Janssen Pharmaceuticals, Inc.Inventors: Jan Theunis Poolman, Bert Jacquemyn, Darren Robert Abbanat, Patricia Ibarra Yon, Peter Wilhelmus Maria Hermans, Michael Thomas Kowarik, Michael Lukas Wetter, Stefan Jochen Kemmler, Micha Andres Häuptle, Veronica Gambillara Fonck, Manuela Mally
-
Patent number: 10532067Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: GrantFiled: October 5, 2017Date of Patent: January 14, 2020Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
-
Publication number: 20190076519Abstract: Fusion proteins comprising a carrier protein and a Human Rhinovirus (HRV) peptide, and immunogenic compositions containing such fusion proteins.Type: ApplicationFiled: August 17, 2018Publication date: March 14, 2019Applicant: GlaxoSmithKline Biologicals S.A.Inventors: Guy BAUDOUX, Mathieu BOXUS, Brigitte COLAU, Martine MARCHAND
-
Publication number: 20190049390Abstract: Apparatus for detecting cracks in optically transparent articles e.g vials, comprising a mount for the article, a light source to direct light at a mounted article, an optical detector positioned to receive light from the light source passed through the article and to generate an electronic signal responsive to received light, first and second (analyzer) polarizers such that light from the light source passes through the first polarizer then through the article, then through the second polarizer on its path to the optical detector, with an optical wave plate positioned between the mount and the second polarizer, and an image processing system to process the electronic signal generated by the optical detector and to indicate the presence or absence of a crack in the article supported on the mount. A method of crack detection using the apparatus is also provided.Type: ApplicationFiled: February 1, 2017Publication date: February 14, 2019Applicant: GlaxoSmithKline Biologicals S.A.Inventor: Romain Marie VEILLON
-
Patent number: 10060928Abstract: Methods for determining the endotoxin content of an aluminum salt preparation for use in medicine are provided. The methods include mixing the aluminum salt with a desorption buffer and separating the aluminum salt from the endotoxin.Type: GrantFiled: June 5, 2014Date of Patent: August 28, 2018Assignee: GlaxoSmithKline Biologicals, S.A.Inventor: Clementine Mascaux
-
Patent number: 10058603Abstract: The disclosure provides immunogenic compositions comprising human picornavirus peptides derived from structural proteins of the virus, constructs comprising the peptides, the peptides themselves and their use in the prevention of picornavirus infection and disease. Particular peptides from VP4 and VP1 are disclosed.Type: GrantFiled: March 13, 2014Date of Patent: August 28, 2018Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Guy Baudoux, Mathieu Boxus, Brigitte Colau, Martine Marchand
-
Patent number: 10039823Abstract: The present invention provides a human dose of an immunogenic composition comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of Quillaja Saponaria Molina presented in the form of a liposome and a lipopolysaccharide wherein said saponin fraction and said lipopolysaccharide are both present in said human dose at a level of below 30 ?g. The present invention further provides an adjuvant composition in a human dose suitable volume comprising between 1 and 30 ?g of a lipopolysaccharide and between 1 and 30 ?g of an immunologically active saponin fraction presented in the form of a liposome.Type: GrantFiled: February 3, 2011Date of Patent: August 7, 2018Assignee: GlaxoSmithKline Biologicals, S.A.Inventor: Pierre Vandepapeliere
-
Publication number: 20180214379Abstract: The present invention relates to the formulation of Adenoviral vectors in an aqueous mixture or freeze dried composition in the presence of amorphous sugar and low salt concentration, its formulation as well as a method for obtaining the dried composition.Type: ApplicationFiled: July 20, 2016Publication date: August 2, 2018Applicant: GlaxoSmithKline Biologicals, S.A.Inventors: Erwan BOURLES, Frederic MATHOT
-
Publication number: 20180015159Abstract: The invention relates to a recombinant human cytomegalovirus (CMV) protein dimeric complex comprising CMV gH protein or a complex-forming fragment thereof, and CMV UL116 or a complex-forming fragment thereof. Also provided herein are nucleic acids encoding said gH/UL116 dimeric complex, host cells for recombinant expression of said gH/UL116 dimeric complex, and the use of said gH/UL116 dimeric complex for use as a vaccine antigen.Type: ApplicationFiled: January 22, 2016Publication date: January 18, 2018Applicant: GlaxoSmithKline Biologicals, S.A.Inventors: Luca BRUNO, Stefano CALO, Andrea CARFI, Mirko CORTESE, Marcello MEROLA
-
Patent number: 9795668Abstract: Particle compositions comprising adsorbed RNA replicons as well as methods of making and using the same are described.Type: GrantFiled: November 23, 2015Date of Patent: October 24, 2017Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Siddhartha Jain, Manmohan Singh, Derek O'Hagan
-
Publication number: 20170209562Abstract: The present disclosure relates to the field of Neisserial immunogenic compositions and vaccines, their manufacture and the use of such compositions in medicine. In particular the present invention relates to compositions and methods involving the factor H binding protein (fHbp) antigen. The present inventors have recognised that fHbp is poorly expressed in neisserial strains of ST269 clonal complex (a subset of strains which seems to be growing in terms of numbers of reported cases of disease attributed to it), and vaccines comprising fHbp may be made more effective against said strains by formulating the vaccine with a further antigen that can elicit protection against these strains.Type: ApplicationFiled: December 6, 2016Publication date: July 27, 2017Applicant: GlaxoSmithKline Biologicals S.A.Inventors: Jan POOLMAN, Nathalie Isabelle DEVOS, Cindy CASTADO, Vincent WEYNANTS
-
Patent number: 9700605Abstract: The present invention provides an immunogenic composition comprising an antigen or antigen composition and an adjuvant composition comprising an oil in water emulsion, wherein said oil in water emulsion comprises 0.5-10 mg metabolizable oil, 0.5-11 mg tocol and 0.1-4 mg emulsifying agent, per human dose.Type: GrantFiled: January 9, 2015Date of Patent: July 11, 2017Assignee: GlaxoSmithKline Biologicals S.A.Inventors: William Ripley Ballou, Jr., Emmanuel Jules Hanon
-
Patent number: 9655845Abstract: This invention generally relates to cationic oil-in-water emulsions that can be used to deliver nucleic acid molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The emulsion particles have an average diameter of about 80 nm to about 180 nm, and the emulsion have an N/P ratio of at least 1.1:1.Type: GrantFiled: July 6, 2012Date of Patent: May 23, 2017Assignee: GlaxoSmithKline Biologicals, S.A.Inventors: Luis Brito, Michelle Chan, Andrew Geall, Derek O'Hagan, Manmohan Singh